Q-omics provides the consensus-scored SPANXN4 profile across patient tissues and cancer cell-line models. SPANXN4 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SPANXN4 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, SPANXN4 RNA expression shows 5,990 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUSC, and STAD as cancer lineages where SPANXN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXN4 survival associations across molecular data types. SPANXN4 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXN4 RNA expression–survival associations across cancer types. High SPANXN4 expression shows unfavorable associations in UCEC, BLCA, LUAD, SARC, ESCA and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SPANXN4 RNA expression.
This table summarizes SPANXN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXN4 shows higher tumor expression in LUSC. The LUSC box plot shows higher SPANXN4 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .013).
This table shows molecular features associated with SPANXN4 in patient tissues and cancer cell lines. In patient samples, SPANXN4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPANXN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
